Drug Search Results
More Filters [+]

Vaniprevir

Alternative Names: vaniprevir, mk-7009, mk7009, mk 7009
Latest Update: 2024-06-21
Latest Update Note: News Article

Product Description

Mechanisms of Action: HCV-NS3/4A Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Japan

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vaniprevir

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hepatitis A|Hepatitis C, Chronic

Phase 2: Hepatitis A|Hepatitis C, Chronic|Hepatitis C|Communicable Diseases

Phase 1: Hepatitis C|Hepatitis C, Chronic|Hepatitis A|Liver Failure|Hepatic Insufficiency

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MK-7009-048

P1

Completed

Hepatitis C, Chronic|Hepatitis A

2013-08-27

MK-7009-043

P3

Completed

Hepatitis A|Hepatitis C, Chronic

2013-07-31

MK-7009-028

P2

Completed

Hepatitis C, Chronic|Hepatitis A

2013-05-29

2009-013053-15

P2

Completed

Hepatitis C

2013-05-29

Recent News Events